Finance

Lists
EVT:FRA
Evotec SE
2,85 €
-1,45%
(-0,042) 1D
9-окт., 08:04:03 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for EVT...
Open
2,80 €
High
2,85 €
Low
2,80 €
Mkt. cap
504,62 млн
Avg. vol.
4,65 миң
Volume
1,80 миң
52-wk high
7,49 €
52-wk low
2,73 €
EPS
-1,11 €
Shares outstanding
148,72 млн
No. of employees
4 миң
Open
2,80 €
High
2,85 €
Low
2,80 €
Mkt. cap
504,62 млн
Avg. vol.
4,65 миң
Volume
1,80 миң
52-wk high
7,49 €
52-wk low
2,73 €
EPS
-1,11 €
Shares outstanding
148,72 млн
No. of employees
4 миң
News stories
From web sources and news partners
Profile
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development. The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more. On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
About Evotec SE
CEO-
Employees4,46 миң
Founded1993
Headquarters-
SectorHealth care
Websiteevotec.com
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
163,89 млн
253,27 млн
156,64 млн
143,48 млн
Cost of goods sold
163,95 млн
174,81 млн
158,21 млн
145,06 млн
Cost of revenue
163,95 млн
174,81 млн
158,21 млн
145,06 млн
Research and development expenses
8,71 млн
9,83 млн
10,08 млн
10,26 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
42,31 млн
44,35 млн
43,79 млн
39,29 млн
Operating expense
43,53 млн
55,25 млн
44,85 млн
87,74 млн
Total operating expenses
207,48 млн
230,06 млн
203,07 млн
232,80 млн
Operating income
-43,59 млн
23,21 млн
-46,42 млн
-89,32 млн
Other non operating income
1,19 млн
-33,96 млн
1,89 млн
-839,00 миң
EBT including unusual items
-42,96 млн
29,46 млн
-122,18 млн
-48,12 млн
EBT excluding unusual items
-43,36 млн
18,35 млн
-47,40 млн
-94,00 млн
Income tax expense
127,00 миң
14,84 млн
-244,00 миң
-1,47 млн
Effective tax rate
-0,30%
50,37%
0,20%
3,06%
Other operating expenses
-7,50 млн
1,07 млн
-9,02 млн
38,20 млн
Net income
-43,09 млн
14,62 млн
-121,94 млн
-46,65 млн
Net profit margin
-26,29%
5,77%
-77,84%
-32,51%
Earnings per share
-0,24
-
-
-
Interest and investment income
841,00 миң
11,84 млн
-
-
Interest expense
-2,28 млн
-
-2,58 млн
-2,97 млн
Net interest expenses
-1,44 млн
11,84 млн
-2,58 млн
-2,97 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-18,27 млн
41,91 млн
-22,60 млн
-64,88 млн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору